MENU

This Small-Cap Pharma Stock Looks Seriously Undervalued

Image source: Getty Images.

In accelerating equity markets, it can be difficult to find value, and one stock that has flown under the radar is Medicure (TSX:MPH). With a market capitalization of roughly $107 million, Medicure is a small-cap stock with serious upside. The company’s strong balance sheet and expanding product pipeline leaves it well positioned to be a key player in the growing cardiovascular therapeutics market.

With the S&P 500 Healthcare Index earning annualized returns of approximately 12% since 2014, there is reason for investors to be bullish on the medical industry. One key driver of health-sector growth is an increasing aging population, which will enhance demand for efficient, affordable care. With this in mind, investors looking for exposure in the healthcare sector will benefit from companies with a specialized focus on delivering treatments to large markets at a reasonable price.

Cardiovascular disease (CVD) is the leading cause of death globally and accounts for a quarter of total annual deaths in the United States. In fact, John Hopkins Medicine estimates that nearly 84 million Americans suffer from some type of CVD. Hence, it is clear that the U.S. provides a robust market for CVD therapeutics, and specialty companies such as Medicure stand to benefit.

Medicure is headquartered in Winnipeg, Manitoba, and has a handful of operating subsidiaries in the U.S. and Barbados. The company targets hospitals with a premier focus on the sale of Aggrastat—a tirofiban hydrochloride injection. Tirofiban actively deters blood clotting, which can dramatically reduce the risk of heart attacks and other cardiovascular events.

In addition to Aggrastat, Medicure has a handful of other cardiovascular therapeutics available to the public. For example, two products currently sold by Medicure include Zypitamag and a sodium nitroprusside injection. Zypitamag works to lower bad cholesterol and the nitroprusside injection offers an immediate solution to high blood pressure.

So, why is Medicure worth a closer look?

1. Strong fundamentals

Over the past few years, the company has consistently generated revenues in the mid to upper $20 million range and has ample cash on the books to potentially build a stronger product pipeline. In addition to having a healthy amount of cash, Medicure’s balance sheet has seen a significant reduction in debt which further stabilizes the company’s financial position. However, if the management team decides to allocate excess cash to research and development (R&D) initiatives, the company could also profit (queue point two).

2. Investment in R&D

Medicure has gradually increased investment in R&D on a year-over-year basis as the company scales up for clinical trial advancement. Diversifying away from the CVD market, Medicure’s product Taradoxal treats a neurological disorder called Tardive Dyskinesia (TD). With no present FDA-approved treatment for TD, Taradoxal could be an impending game-changer that is currently in phase IIa of clinical trials.

3. Historical return on assets

Through a series of transactions spanning from 2014 to 2017, Medicure secured a majority interest in Apicore. In late 2017, the company sold Apicore for US$105 million, which represented a strong return on investment.

Conclusion

Given the aforementioned catalysts, Medicure should be added to the watch list for the possibility of wholesome returns.

Free investor brief: Our 3 top SELL recommendations for 2018

Just one ticking time bomb in your portfolio can set you back months – or years – when it comes to achieving your financial goals. There’s almost nothing worse than watching your hard-earned nest egg dwindle!

That’s why The Motley Fool Canada’s analyst team has put together this FREE investor brief, including the names and tickers of 3 TSX stocks they believe are set to LOSE you money.

Stock #1 is a household name – a one-time TSX blue chip that too many investors have left sitting idly in their accounts, hoping the company’s prospects will improve (especially after one more government bailout).

Still, our analysts rate this company a firm SELL.

Don’t miss out. Click here to see all three names right now.

Fool contributor Tom Hoy has no position in the companies mentioned.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.